Ym155 Clinical Trial

Survivin Inhibition Is Critical For Bcl-2 Inhibitor-Induced ...
Survivin Inhibition Is Critical for Bcl-2 Inhibitor-Induced Apoptosis in Hepatocellular Carcinoma Cells Xiangxuan Zhao to provide primary preclinical data for future clinical trial with ABT (1 M) or combination of ABT-263 (1 M) and YM155 (1 mM) for up to 6 h as indicated. Then ... Retrieve Doc

Financial Results For The 1Q/FY 2009 Ending March 31, 2010
YM155 (J) ASP0265 ASP3652 ASP7035 Diabetes Cardiology Renal YM311(J) * ASP1517(J) * Others clinical trial material as the development of candidate compounds obtained through fermentation-based drug discovery research Construction : ... Fetch Doc

Ongoing trial assessing clinicopathologic parameters as well as molecular correlates in patients with HNSCC of unknown primary origin. molecular correlates portion of this study investigating correlation of molecular LOH markers with histopathologic and clinical autofluorescence variables. ... Read Here

I. PUBLICATIONS Books And Monographs
I. PUBLICATIONS Books and Monographs Lopez-Chavez, A. Sandler, A. Chapter 3. (YM155, survivin suppressor) and Thymic Malignancies trial): A radical redesign of clinical trial structure—Use of mass customization and product postponement. J Clin Oncol 31, 2013 ... Read Document

trial Research Ethics Of Recruitment Recruit To NAME OF TRIAL ...
Delivering Clinical Research June 2013 NAME OF TRIAL Research Ethics No (REC) Target no of Patients Recruitment Deadline Trial Status Did the trial Recruit to ... Fetch Document

DHA-paclitaxel - Wikipedia, The Free Encyclopedia
DHA-paclitaxel (or Taxoprexin) Clinical trials. In 2007, a phase II clinical trial reported "modest activity in patients with oesophago-gastric cancer". [2] References This antineoplastic or immunomodulatory drug article is a stub ... Read Article

Supplementary Webappendix - TheLancet.com Homepage
Supplementary webappendix A phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: multiple responses observed in patients with relapsed et al. Efficacy and safety of YM155 in relapsed/refractory non-Hodgkin’s lymphoma patients enrolled in a phase ... Visit Document

OURNAL OF CLINICAL ONCOLOGY - Jco.ascopubs.org
Phase III Trial of Consolidation Therapy With Yttrium-90 Official Journal of the American Society of Clinical Oncology Vol 26, No 32 CONTENTS November 10, 2008 Journal of Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin Anthony W. Tolcher ... Return Doc

Diagnosis And Management Of Lymphoma
30 • Clinical Lymphoma & Myeloma July 2006 Abstract on the FL2000 randomized trial com-bining rituximab with CHVP (cyclo-phosphamide/doxorubicin/etoposide/ dose-escalation study of YM155, 3 of 5 patients with DLBCL, all of whom were ... Read More

Www.uhs.nhs.uk
TRAPEZE -Phase II effiacacy and safety clinical trial. RHM CAN0534. A phase II multicenter, open-label study of YM155 in refractory diffuse large B-cell lymphoma (DLBCL) subjects. YM155 in refractory diffuse large B-cell lymphoma. RHM CAN0551. ... Return Doc

Www.ncri-pet.org.uk
A multi-centre Randomised Phase II Clinical Trial Comparing Oxaliplatin (Eloxatin), Capecitabine YM155 + rituximab NCT01070485 UK multicentre Sheffield and others In work-up Leeds and others Sheffield Algeta ASA Anne-Kirsti Aksnes, PhD Alpharadin ... View Document

Original Article Sepantronium Is A DNA Damaging Agent That ...
Clinical trial [20]. These patients were all previ- In a phase 1 clinical dose-escalation trial [22], volasertib was found to be safe and had trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, ... Document Viewer

UNIVERSITY OF MIAMI Sylvester Comprehensive Cancer Center ...
Sylvester Comprehensive Cancer Center . Curriculum Vitae . 10/08/2014 . I. PERSONAL Name: Ariel Lopez-Chavez (YM155, survivin suppressor and Thymic Malignancies trial): A radical redesign of clinical trial structure—Use of mass customization and product postponement. J Clin Oncol 31 ... Content Retrieval

Financial Results For The 1Q/FY 2009 Ending March 31, 2010
August 3, 2009 Yoshihiko Hatanaka CFO and Chief Strategy Officer Astellas Pharma Inc. Financial Results for the 1Q/FY 2009 Ending March 31, 2010 ... Get Content Here

Our Approach Value Creation - Astellas Pharma Australia
YM150 Clinical trial status ASTELLAS PHARMA INC. ANNUAL REPoRT 2009 ASTELLAS PHARMA INC. ANNUAL REPoRT 2009 pg.21. Of these, YM155, ASP3550, and AGS-1C4D4 are in Phase 2. In addition, we aim to expand our oncology pipeline even further ... Get Doc

Survivin - Wikipedia, The Free Encyclopedia
Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5, is a protein that, in humans, is encoded by the BIRC5 gene. ... Read Article

Association Of Long-term Administration Of The Survivin MRNA ...
Oligonucleotide LY2181308 as part of a First-in-Human Dose trial. After 18 months of treatment, The small-molecule survivin inhibitor YM155 also has been associated with kidney toxicity and hence Figure1. Pharmacokinetic The clinical pattern of hypertension, transient throm- ... View Doc

SOURCE (OR PART OF THE FOLLOWING SOURCE): FULL BIBLIOGRAPHIC ...
Phase I/II clinical trials with YM155 show promising results.1,2,4,5 Also in vitro and in Phase I/II clinical trial in pediatric neuroblastoma. A preclinical evaluation of patient selection biomarkers and biomarkers for efficacy is needed. ... Get Content Here

YM155 retains nearly identical potency across a large range of cancer cell lines, • FV-162: upcoming Phase I/II clinical trial in R/R myeloma with Dr. Suzanne Trudel, Princess Margaret Cancer Centre. • Fluorinated-BRD4 inhibitor: IND candidate ... Get Document

Date Range Jan 2009 To Present Hospital Site --- All Sites ...
YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) gliomas Clinical Trial Research False Hospital for Sick Children, Dr. Eric BuffetFunded 2005/09 present Van Der Jagt, Richard A phase II Clinical Trial of Lenalidomide for T- ... Access This Document

Recent Developments In Prostate Cancer Biomarker Austin ...
Investigation in late phase clinical trials.Recent novel prostate cancer biomarkers that made it through clinical trials and their relevance as drug targets are summarized.This review emphasizes the importance of specific prostate cancer biomarkers and their potentials as ... Read Document